FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial
|
|
NovaRx Corporation announced today that the Company has successfully negotiated and received FDA approval for a Special Protocol Assessment (SPA) Protocol Amendment to the pivotal Lucanix® Phase III clinical trial in patients... [read full story]
View other selected articles:
US pay czar OKs changes for 2 top BofA executives
Chief Financial Officer Joe. L. Price and mortgage unit President Barbara J. Desoer will earn less salary in 2009 than they did last year following approval by the officer of the special master for TARP Executive Compensation,...
Putting Dubai in Perspective (at Barrons.com)
It is this observation, delivered in a March 2007 speech by Federal Reserve governor Kevin Warsh: "Liquidity is confidence." So when Dubai World, the corporate affiliate of the emirate of Dubai, sought to suspend debt payments...
China Crescent Enterprises, Inc. to Recap $30 Million in Revenue and Record $1.8 Million in Net Inco
China Crescent Enterprises, Inc. (OTCBB: CCTR) has scheduled a shareholder update Webcast for Tuesday, December 1, 2009. The Webcast agenda includes a review of the recently released letter to shareholders on the enhanced...
12 Years Of Patent Protection For Biologics Based Research And Development Creates Buying...
67 WALL STREET, New York - November 28, 2009 - The Wall Street Transcript has recently published its Q4 2009 Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70 page...
International Editions
English - US | English - UK | Deutsch | Français | Español - España | Português - Portugal | Italiano | Čeština | Русский (Russian) | عربي (Arabic) | 中文（简）(Simplified Chinese) | Español - México | Português - Brasil | 한국어 (Korean) | English - India
